Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Neoplasms 10Glioblastoma 9Fallopian Tube Neoplasms 8Colorectal Neoplasms 8Breast Neoplasms 8Lung Neoplasms 7Rectal Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Brain Neoplasms 6Prostatic Neoplasms 4Melanoma 4Uterine Cervical Neoplasms 3Solitary Fibrous Tumor, Pleural 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Advanced Solid Tumor 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × cediranib × Clear all
NCT02893917 2026-04-13

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
90 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT00436956 2018-10-09

AZD2171 to Treat Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
59 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00527124 2018-08-09

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Terminated
57 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT01260688 2018-08-08

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡